ESTRO Multidisciplinary Management of Breast Cancer 2017

Cardiovascular toxicity – trastuzumab

• Trastuzumab is associated with cardiomyopathy

• Assesment of LVEF is indicated

• Data combination trastuzumab and radiotherapy • NCCTG N9831 trial: No increased cardiotoxicity with concurrent treatment • Late effects are not known (FU 3.7 years) • Concurrent trastuzumab with radiotherapy (with modern techniques, cardiac sparing) may be continued

Perez, JCO 2011

19-9-2017